Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 142,207
  • Shares Outstanding, K 130,465
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,170 K
  • EBIT $ -103 M
  • EBITDA $ -103 M
  • 60-Month Beta 1.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 465.60% (+67.17%)
  • Historical Volatility 107.10%
  • IV Percentile 85%
  • IV Rank 56.53%
  • IV High 773.64% on 10/21/25
  • IV Low 65.03% on 10/20/25
  • Expected Move (DTE 19) 0.2975 (27.29%)
  • Put/Call Vol Ratio 0.30
  • Today's Volume 573
  • Volume Avg (30-Day) 589
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 18,742
  • Open Int (30-Day) 21,389
  • Expected Range 0.7925 to 1.3875

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.10
  • Number of Estimates 6
  • High Estimate -0.05
  • Low Estimate -0.20
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9758 +11.70%
on 03/02/26
1.5100 -27.81%
on 03/12/26
+0.0700 (+6.86%)
since 02/27/26
3-Month
0.5062 +115.33%
on 12/30/25
1.5100 -27.81%
on 03/12/26
+0.5287 (+94.19%)
since 12/26/25
52-Week
0.5062 +115.33%
on 12/30/25
1.5100 -27.81%
on 03/12/26
-0.1500 (-12.10%)
since 03/27/25

Most Recent Stories

More News
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 –

IMUX : 1.0900 (-13.49%)
Immunic to Participate in Investor Conferences in March

NEW YORK , March 3, 2026 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...

IMUX : 1.0900 (-13.49%)
Immunic: Q4 Earnings Snapshot

Immunic: Q4 Earnings Snapshot

IMUX : 1.0900 (-13.49%)
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 –

IMUX : 1.0900 (-13.49%)
Immunic Announces Closing of Oversubscribed Private Placement Financing

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –

IMUX : 1.0900 (-13.49%)
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –

IMUX : 1.0900 (-13.49%)
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity –

IMUX : 1.0900 (-13.49%)
Immunic Highlights 2025 Accomplishments and Upcoming Milestones

– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 –

IMUX : 1.0900 (-13.49%)
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...

IMUX : 1.0900 (-13.49%)
Immunic: Q3 Earnings Snapshot

Immunic: Q3 Earnings Snapshot

IMUX : 1.0900 (-13.49%)

Business Summary

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis....

See More

Key Turning Points

3rd Resistance Point 1.4067
2nd Resistance Point 1.3433
1st Resistance Point 1.2167
Last Price 1.0900
1st Support Level 1.0267
2nd Support Level 0.9633
3rd Support Level 0.8367

See More

52-Week High 1.5100
Fibonacci 61.8% 1.1265
Last Price 1.0900
Fibonacci 50% 1.0081
Fibonacci 38.2% 0.8897
52-Week Low 0.5062

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.